Barry, OppHub America Desk · · Source: prnewswire-all
Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026
Based on reporting from prnewswire-all.
Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026 USA - English USA - English News provided by BioArctic Oct 28, 2026, 06:27 ET STOCKHOLM , October 28, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for th
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
USA - English USA - English News provided by BioArctic Oct 28, 2026, 06:27 ET STOCKHOLM , October 28, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the third quarter 2026, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 32.2 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 203.8 million, which is an increase of approximately 74 percent compared to the royalty recorded by BioArctic for the third quarter of 2025. BioArctic's report for the third quarter of 2026 will be published on November 25, 2026, at 08:00 am CET. This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: October 28, 2026 at 6:57 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
Alzheimer's Therapeutics
An Alzheimer's drug called Leqembi brought in strong sales this quarter, boosting the royalty payments for the companies that helped create it. This matters to investors because it shows the drug is selling better and making more money over time.
What changed
Partner Eisai published preliminary global revenue of JPY 32.2 billion for Leqembi in Q3 2026, boosting BioArctic's royalty by 74% year-over-year.
Who wins / who loses
Biotech firms and partners commercializing approved Alzheimer's treatments benefit, while competitors in the neurology pipeline face pressure to match commercial execution.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $BIIBBuild slowly — only if it fits your plan
Biogen helps sell this medicine, so higher sales can mean better business results for the company.
View $BIIB chart → · End-of-day delayed data
Peer
- $LLYWatch — track, don’t rush
Eli Lilly makes a similar competing drug, so they are closely watched to see how the overall market is growing.
View $LLY chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should skip options here and stick to regular stock shares or ETFs if they want to participate.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Monitor upcoming clinical trial readouts for competing Alzheimer's pipeline treatments.
What would break this thesis
- Slowing quarter-over-quarter sales growth for Leqembi or unexpected safety hurdles.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from prnewswire-all.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).